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Abstract
Summary Numerous observational studies suggest that bisphosphonates reduce mortality. This study showed that bisphospho-
nate use is associated with lower mortality within days of treatment, although the association was not significant until the second
week. Such an early association is consistent with confounding, although an early treatment effect cannot be ruled out.
Introduction The purpose of this study was to examine whether confounding explains why numerous observational studies show
that bisphosphonate use is associated with lower mortality. To this end, we examined how soon after treatment initiation a lower
mortality rate can be observed. We hypothesized that, due to confounding, the association would be observed immediately.
Methods This was a retrospective cohort study of hip fracture patients discharged from Swedish hospitals between 1 July 2006 and
31 December 2015. The data covered 260,574 hip fracture patients and were obtained from the Swedish Hip Fracture Register and
national registers. Of the 260,574 patients, 49,765 met all eligibility criteria and 10,178 were pair matched (bisphosphonate users to
controls) using time-dependent propensity scores. The matching variables were age, sex, diagnoses, prescription medications, type
of hip fracture, type of surgical procedure, known or suspected dementia, and physical functioning status.
Results Over a median follow-up of 2.8 years, 2922 of the 10,178 matched patients died. The mortality rate was 7.9 deaths per
100 person-years in bisphosphonate users and 9.4 deaths in controls, which corresponded to a 15% lower mortality rate in
bisphosphonate users (hazard ratio 0.85, 95% confidence interval 0.79–0.91). The risk of death was lower in bisphosphonate
users from day 6 of treatment, although the association was not significant until the second week.
Conclusion Bisphosphonate use was associated with lower mortality within days of treatment initiation. This finding is consistent
with confounding, although an early treatment effect cannot be ruled out.
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Introduction
Bisphosphonates, inhibitors of bone resorption, are primarily
used in osteoporosis patients to reduce fracture rates [1], but
some research suggests that bisphosphonates also reduce mor-
tality rates. In a randomized controlled trial, Lyles et al. reported
that the intravenous bisphosphonate zoledronic acid significant-
ly reduced mortality by 28% in hip fracture patients [2]. Such
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an effect was not, however, detected in other trials of zoledronic
acid or other bisphosphonates [3–8]. Although one meta-
analysis did detect a significant effect of bisphosphonates on
mortality [9], another meta-analysis did not [10].
In contrast to the uncertain evidence provided by random-
ized controlled trials, numerous observational studies show
that bisphosphonate use is associated with lower mortality
[11, 12, 21, 22, 13–20]. These results could be confirmation
that bisphosphonates indeed have a beneficial effect on mor-
tality. However, observational studies are susceptible to con-
founding [23], so these results could also be a reflection of
better overall health in bisphosphonate-treated patients than in
non-treated patients. In one study, Bondo et al. concluded that
confounding is likely because they found a lower mortality
rate in patients who had received only one prescription for a
bisphosphonate (≤ 84 days of treatment) [24]; they reasoned
that such an early treatment effect is unlikely. In another study,
Sing et al. reasoned that a treatment effect within 30 days
would be unlikely, so they excluded patients with < 30 days
of treatment in a sensitivity analysis [12]. Because bisphos-
phonate use was still associated with lower mortality after this
exclusion, the authors concluded that confounding was un-
likely. However, this analysis would not eliminate confound-
ing in patients with ≥ 30 days of treatment, so a better ap-
proach would have been to examine whether there was an
association in the first 30 days of treatment, when no effect
was expected.
To examine further the possibility of confounding, we
aimed to clarify how soon after initiation of bisphosphonate
treatment a lower mortality rate can be observed. We hypoth-
esized that, due to confounding, the association would be ob-
served immediately. We tested this hypothesis in a retrospec-
tive cohort study of Swedish hip fracture patients.
Methods
Data sources
Hip fracture patients were identified through the Swedish Hip
Fracture Register. This database was created in 1988 to im-
prove the quality of care after hip fractures in Sweden, and it
covers an estimated 87% of hip fracture patients in the country
[25, 26]. The data are collected from hospital wards using
standardized forms, which are filled out by a health care pro-
fessional, usually a nurse [26]. Available variables that were
used in this study include type of fracture, type of surgical
procedure, housing situation (e.g., private home or nursing
home), mental functioning status (e.g., known or suspected
dementia), and physical functioning status (e.g., walking abil-
ity before fracture, use of walking aid before fracture, and
American Society of Anesthesiologists [ASA] Physical
Status Score]).
We collected medical data about the hip fracture patients
from the National Patient Register and the Swedish Cancer
Register. The National Patient Register is a database of inpa-
tient admissions and specialist (non-primary care) outpatient
visits [27]. All public and private healthcare providers in
Sweden have been required to report inpatient admissions
since 1987 and specialist outpatient visits since 2001.
Variables available in the National Patient Register include a
primary diagnosis, secondary diagnoses, and the date of the
visit or the dates of admission and discharge. Diagnoses have
been coded according to the 10th revision of the International
Classification of Diseases (ICD-10) since 1997 and according
to earlier revisions prior to this year. The Swedish Cancer
Registry is a database of cancer diagnoses, coded according
to the ICD. All health care providers have been required to
report new cases of cancer to this registry since 1958 [28].
We obtained data about prescription medication use from
the Prescribed Drug Register, which contains information
about prescription medications dispensed at pharmacies in
Sweden since July 2005 [29]. Available variables include
Anatomical Therapeutic Chemical (ATC) code, pack size,
number of packs dispensed, and date of dispensation.
We collected mortality data from the Cause of Death
Register, which records the date and cause of death of resi-
dents of Sweden since 1961 [30]. The cause of death is deter-
mined by the physician who verified the death, and it is coded
according to the ICD-10.
We obtained emigration data from the Register of the Total
Population. This and the abovementioned databases were
linked using personal identity numbers, which are issued by
the Swedish Tax Agency to residents of Sweden upon birth or
immigration. These numbers are unique, although they are
occasionally reused if a person immigrating to Sweden has
the same date of birth as a deceased person. For privacy rea-
sons, we received data files in which each personal identity
number had been replaced by a random identifier, generated
by Statistics Sweden.
The present study was approved by the Regional Ethical
Review Board in Umeå, Sweden (Dnr 2013-86-31M, 2013-
304-32M). The review board waived the requirement of
obtaining informed consent.
Study design
In this analysis, we included hip fracture patients who were
discharged alive from 1 July 2006 to 31 December 2015 (the
accrual period). Patients who sustained more than one hip
fracture during this period were included from the date of
discharge following their first hip fracture. Patients were ex-
cluded if their latest personal identity number was unavailable,
if they had a reused personal identity number, or if they had
missing data about a confounder obtained from the Swedish
Hip Fracture Register (referred to as hospitalization data).
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To reduce confounding in observational studies, the
epidemiology literature has recommended researchers to
imitate the eligibility criteria of randomized controlled
trials [31, 32]. Therefore, we imitated the eligibility
criteria of the trial by Lyles et al., which reported that a
bisphosphonate significantly reduced mortality [2]. We
did this by excluding subjects for the following reasons:
age < 50 years; dispensation of bisphosphonate in the last
year; radiotherapy or diagnosis of cancer in the last
5 years; diagnosis of chronic kidney disease, solid organ
transplantation, hypercalcemia, hyperparathyroidism, or
metabolic bone disease other than osteoporosis (osteogen-
esis imperfecta, osteomalacia, or Paget’s disease of bone);
prior use of parathyroid hormone or strontium ranelate;
use of systemic corticosteroids in the last 6 months; path-
ologic hip fracture; immobility prior to hip fracture; and
limited life expectancy (defined here as ASA Physical
Status Score ≥ 4). Classification codes for the mentioned
diagnoses and medications are available in Supplemental
Table 1. We did not have access to variables to exclude
for high-trauma hip fracture, inability or unwillingness to
take oral bisphosphonates, allergy to bisphosphonates,
uveitis, iritis, tibolone or sodium fluoride use, pregnancy,
or high level of serum alkaline phosphatase [2].
Subjects were classified as bisphosphonate users from the
date they were first dispensed a bisphosphonate. They
remained in the bisphosphonate group for the duration of fol-
low-up, as our aim was not to examine the effect of adherence
or persistence.
The main study outcome was all-cause mortality.
Secondary outcomes were death from one of the following
causes: cardiovascular disease; cerebrovascular disease; respi-
ratory disease; dementia, Alzheimer’s disease, or senility; neo-
plasm; and injury from accident. ICD-10 codes for these
causes are available in Supplemental Table 1.
The confounders we considered and controlled for are
listed in Table 1. The confounders were selected because they
were used in a post-hoc analysis of the trial by Lyles et al. [33],
in previous observational studies of bisphosphonates and mor-
tality [12, 13, 22, 14–21], or in FRAX, a common fracture risk
assessment tool. Classification codes for medications and di-
agnoses are available in Supplemental Table 1.
Statistical analysis
The eligible cohort was followed from date of discharge until
death, emigration, or 31 December 2016 (whichever came
first). Bisphosphonate users accrued follow-up time to the
nonuser group until the date when they were first dispensed
a bisphosphonate. Hazard ratios were calculated using Cox
regression, a model in which bisphosphonate use and con-
founders were coded as time-varying variables.
To examine the effect of bisphosphonates as a function of
treatment duration, it was necessary to change the start of
follow-up from date of discharge to date of treatment initia-
tion. Therefore, our main analysis was not the analysis of the
full eligible cohort but an analysis of a matched sub-cohort, in
which bisphosphonate users were followed from the date they
were first dispensed a bisphosphonate and matched controls
were followed from a comparable baseline date. This baseline
date was the date (post hip fracture) that occurred after the
same number of days as treatment initiation did in the corre-
sponding bisphosphonate user.
The matching method we used was time-dependent pro-
pensity score matching, which enables propensity-score
matching when treatment is time varying [34, 35]. It involves
matching a patient who receives treatment at a particular time
to a patient who has not received treatment by that same time,
but who perhaps later received treatment. In our case, time
was counted as days since hospital discharge. By including
later-treated patients in the control group, time-dependent pro-
pensity score matching prevents the control group from
consisting solely of patients who are never considered for
treatment and who therefore are likely to be healthier than
treated patients [34]. It also prevents immortal-time bias [36].
Propensity scores were estimated using Cox regression
with the variables listed in Table 1. The matching algorithm
was one-to-one nearest neighbor (psmatch2 program in Stata).
We used a caliper of 20% of the standard deviation of propen-
sity scores. Confounder balance was assessed using standard-
ized mean differences; differences of < 0.1 were considered
negligible [37].
In the analysis of the matched cohort, confidence intervals
for hazard ratios were estimated using robust standard errors
[38]. The proportional hazards assumption was not assessed.
Instead, we examined whether the relative risk of death
changed over time by plotting the ratio of the Kaplan-Meier
curve for bisphosphonate users to that for controls [39].
Pointwise confidence intervals were obtained using the boot-
strap percentile method [39], based on 1000 bootstrap repli-
cates. To take account of the matching, we bootstrap sampled
matched pairs instead of individual subjects.
A subgroup analysis was conducted by type of bisphospho-
nate. In this analysis, bisphosphonate users were censored
upon dispensation of a different bisphosphonate. Two sensi-
tivity analyses were performed. First, subjects were excluded
or censored if they received an osteoporosis medication other
than a bisphosphonate. Second, analyses were rerun including
only subjects discharged to a private home, as osteoporosis
medications taken in nursing homes and other institutions may
be underreported in the Prescribed Drug Register [29].
Missing days of the month were imputed as the first of the
month. Missing months were imputed as January. Missing
years were imputed as the start the study period (1
July 2006). All statistical analyses were performed in Stata
Osteoporos Int (2019) 30:1973–1982 1975
Table 1 Baseline characteristics
Matched cohort
Variable Eligible cohort BP Control SMD
N 49,765 5089 5089 –
Age, mean (SD), years 81 (9) 76 (8) 76 (9) 0.01
Female sex, n (%) 34,844 (70.0) 4145 (81.5) 4121 (81.0) 0.01
Months between discharge and baseline, median (IQR) – 5 (2–13) 5 (2–13) –
Hospitalization data
Days of hospital stay, mean (SD) 9 (6) 8 (5) 8 (5) 0.00
Type of hip fracture, n (%)
Cervical 27,594 (55.5) 2886 (56.7) 2805 (55.1) 0.03
Intertrochanteric 18,411 (37.0) 1823 (35.8) 1929 (37.9) 0.04
Subtrochanteric 3760 (7.6) 380 (7.5) 355 (7.0) 0.02
Admitted from private home, n (%) 36,472 (73.3) 4709 (92.5) 4730 (93.0) 0.02
Discharged to private home, n (%) 17,130 (34.4) 2739 (53.8) 2734 (53.7) 0.00
Known/suspected dementia, n (%) 16,110 (32.4) 519 (10.2) 482 (9.5) 0.02
Walking aid before fracture, n (%) 24,800 (49.8) 1625 (31.9) 1529 (30.1) 0.04
Walking ability before fracture, n (%)
Walked outdoors alone 32,077 (64.5) 4382 (86.1) 4410 (86.7) 0.02
Walked outdoors with company 4035 (8.1) 208 (4.1) 202 (4.0) 0.01
Walked indoors alone 10,824 (21.8) 430 (8.5) 412 (8.1) 0.01
Walked indoors with company 2829 (5.7) 69 (1.4) 65 (1.3) 0.01
ASA physical status score, n (%)
1 4486 (9.0) 769 (15.1) 730 (14.3) 0.02
2 22,423 (45.1) 2757 (54.2) 2841 (55.8) 0.03
3 22,856 (45.9) 1563 (30.7) 1518 (29.8) 0.02
Diagnoses, n (%)
Angina pectoris 7078 (14.2) 551 (10.8) 545 (10.7) 0.00
Arteriosclerosis 1597 (3.2) 147 (2.9) 162 (3.2) 0.02
Atrial fibrillation/flutter 9558 (19.2) 774 (15.2) 760 (14.9) 0.01
COPD 1029 (2.1) 139 (2.7) 139 (2.7) 0
Diabetes mellitus 7094 (14.3) 681 (13.4) 705 (13.9) 0.01
Non-hip fracture in the last 5 years 9957 (20.0) 1098 (21.6) 1072 (21.1) 0.01
Heart failure 6932 (13.9) 495 (9.7) 469 (9.2) 0.02
Hypercholesterolemia/hyperlipidemia 4260 (8.6) 554 (10.9) 585 (11.5) 0.02
Acute renal failure 560 (1.1) 51 (1.0) 47 (0.9) 0.01
Mental/behavioral disorder due to alcohol use 2545 (5.1) 282 (5.5) 286 (5.6) 0.00
Myocardial infarction 4940 (9.9) 332 (6.5) 313 (6.2) 0.02
Osteoporosis 4545 (9.1) 1325 (26.0) 1344 (26.4) 0.01
Rheumatoid arthritis 759 (1.5) 130 (2.6) 118 (2.3) 0.02
Stroke 7447 (15.0) 594 (11.7) 590 (11.6) 0.00
Medications, n (%)
Antidiabetic agents 6164 (12.4) 600 (11.8) 630 (12.4) 0.02
Antithrombotic agents 31,971 (64.2) 3682 (72.4) 3685 (72.4) 0.00
Lipid-lowering agents 13,856 (27.8) 1720 (33.8) 1752 (34.4) 0.01
Calcium/vitamin D 10,247 (20.6) 4617 (90.7) 4593 (90.3) 0.02
Denosumab 66 (0.1) 6 (0.1) 3 (0.1) 0.02
Raloxifene 159 (0.3) 27 (0.5) 36 (0.7) 0.02
BP bisphosphonate, SMD standardized mean difference, ASA American Society of Anesthesiologists, COPD chronic obstructive pulmonary disease
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(version 15) and R (version 3.5.3), with the Rstudio interface.
We did not have a pre-specified analysis plan.
Results
Eligible cohort and matched cohort
Data were available for 260,574 hip fracture patients, of
whom 49,765 met all eligibility criteria (Fig. 1).
Bisphosphonates were dispensed to 12% (n = 6043) of this
eligible cohort during follow-up, a median of 2.8 years (mean
3.3 years). Matching resulted in a sub-cohort of 5089 bisphos-
phonate users and 5089 controls with similar baseline charac-
teristics (Table 1). Compared to the average hip fracture pa-
tient in the eligible cohort, matched bisphosphonate users
were younger, more often female, had a better physical func-
tioning status, more often lived in a private home, had diag-
nosed osteoporosis, and received prescription calcium and/or
vitamin D, and less often had dementia or cardiovascular dis-
ease. However, bisphosphonate users had more often received
antithrombotic or lipid-lowering agents (Table 1).
In the matched cohort, the most commonly dispensed
bisphosphonates were alendronate (92%, n = 4689),
risedronate (4%, n = 221), and zoledronic acid (3%, n =
161). Seventeen percent (n = 882) of matched controls started
bisphosphonate treatment during follow-up. Five percent (n =
232) of matched bisphosphonate users switched to a different
bisphosphonate during follow-up. The median follow-up was
2.8 years (mean 3.3 years).
Mortality
Table 2 provides mortality rates and hazard ratios for the full
eligible cohort and for the matched cohort. In the full cohort,
bisphosphonate use was associated with a 55% lower mortal-
ity rate before adjustment for confounders (hazard ratio [HR]
0.45, 95% confidence interval [CI] 0.43–0.48). After adjust-
ment for confounders, the association weakened but remained
(fully-adjusted HR 0.85, 95% CI 0.80–0.90). A similar asso-
ciation was observed in the matched cohort (HR 0.85, 95% CI
0.79–0.91).
The analysis of the matched cohort showed that the asso-
ciation between alendronate use and mortality was similar to
the association between risedronate use and mortality
(Table 2). Use of zoledronic acid, however, was associated
with higher mortality (Table 2). Bisphosphonate use was as-
sociated with a lower or similar rate of mortality due to spe-
cific causes (Table 3).




- 7 unavailable personal identity number
- 152 reused personal identity number
- 1412 missing date of hospital discharge
- 135,219 discharged outside of accrual period
- 44,982 missing data about confounder (hospitalization data)
- 2669 discharged dead
- 964 age <50 years upon discharge
- 4716 bisphosphonate dispensation in the last 12 months
- 6901 cancer or radiotherapy in the last 5 years
- 2751 chronic kidney disease
- 6 solid organ transplantation
- 126 hypercalcemia
- 558 metabolic bone disease other than osteoporosis
- 137 use of parathyroid hormone or strontium ranelate
- 4158 systemic corticosteroid use in the last 6 months
- 732 pathologic hip fracture
- 1960 immobile prior to hip fracture
- 3359 limited life expectancy (ASA Phyical Status score )
Fig. 1 Cohort selection
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For the matched cohort, Fig. 2 displays Kaplan-Meier
curves and the ratio of these curves (the relative risk of death)
over 3 years of follow-up. As shown, the risk of death was
lower in bisphosphonate users early after treatment initiation,
although there was an initially increased risk. Figure 3 shows
that the initial increase was based on < 5 cases in bisphospho-
nate users and < 4 cases in controls. Furthermore, the risk was
lower in bisphosphonate users from day 6 of treatment, al-
though the association was not significant until the second
week because the confidence interval for the relative risk o-
verlapped 1 until this time (Fig. 3). Both in Fig. 2 and Fig. 3,
the confidence intervals are plotted from day 6 because the
small number of deaths prior to this day led to undefined
estimates of relative risk in some bootstrap replicates (that is,
when the risk of death was 0% in the control group, the
denominator).
Sensitivity analyses
The association between bisphosphonate use and mortality
did not change substantially when we excluded and censored
patients who used an osteoporosis medication other than a
bisphosphonate (HR 0.84 in the matched cohort, 95% CI
0.78–90). Similarly, the association did not change substan-
tially when we included only patients discharged to a private
home (HR 0.81 in the matched cohort, 95% CI 0.72–0.91).
Table 2 Bisphosphonate use and mortality
Incidence rate/100 person-years (number of deaths)
Cohort BP Control HR (95% CI) P
Entire eligible cohort
Unadjusted 7.5 (1460) 17.5 (24962) 0.45 (0.43–0.48) < 0.001
Adjusted for age and sex 0.66 (0.62–0.70) < 0.001
Adjusted for age, sex, medications and diagnoses 0.70 (0.66–0.74) < 0.001
Adjusted for age, sex, medications, diagnoses, length
of hospitalization, type of hip fracture, known/suspected
dementia, and physical functioning status*
0.85 (0.80–0.90) < 0.001
Matched cohort
Total 7.9 (1313) 9.4 (1609) 0.85 (0.79–0.91) < 0.001
Alendronate 7.7 (1167) 9.5 (1486) 0.82 (0.76–0.89) < 0.001
Risedronate 8.3 (83) 9.4 (69) 0.84 (0.61–1.15) 0.27
Zoledronic acid 11.2 (48) 7.7 (45) 1.51 (1.00–2.28) 0.048
BP bisphosphonate, HR hazard ratio, CI confidence interval
*Physical functioning status includes the following variables: admitted from private home, discharged to private home, use of walking aid before
fracture, walking ability before fracture, and American Society of Anesthesiologists physical status score
Table 3 Bisphosphonate use and
cause-specific mortality in the
matched cohort
Number (%) of deaths
Cause BP Control HR (95% CI) P
All causes 1313 (100) 1609 (100) 0.85 (0.79–0.91) < 0.001
Cardiovascular 422 (32.1) 505 (31.4) 0.87 (0.76–0.99) 0.03
Arrhythmia 55 79 0.72 (0.51–1.01) 0.06
Cerebrovascular 123 (9.4) 157 (9.8) 0.82 (0.64–1.03) 0.09
Respiratory 123 (9.4) 152 (9.4) 0.84 (0.66–1.06) 0.14
Pneumonia 36 46 0.81 (0.52–1.25) 0.34
Dementia/Alzheimer’s disease/senility 169 (12.9) 239 (14.9) 0.74 (0.61–0.90) 0.003
Neoplasm 219 (16.7) 233 (14.5) 0.97 (0.80–1.16) 0.73
Injury from accident 40 (3.0) 54 (3.4) 0.76 (0.51–1.15) 0.20
Other 208 (15.8) 254 (15.8) 0.85 (0.71–1.02) 0.08
Unspecified 9 (0.7) 15 (0.9) 0.62 (0.27–1.43) 0.26
BP bisphosphonate, HR hazard ratio, CI confidence interval
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Discussion
The results showed that bisphosphonate use was associated
with lower mortality in hip fracture patients. The risk of death
was lower in bisphosphonate users from day 6 of treatment,
although the exact timing was unclear due to statistical uncer-
tainty, resulting from an initially small number of deaths.
A lower mortality rate soon after treatment initiation is
consistent with a confounded association, as confounding im-
plies a difference between study groups at baseline.
Confounding could have arisen for at least two reasons.
First, physicians may be more likely to prescribe
bisphosphonates to patients with a decent life expectancy.
This explanation is supported by our data, as bisphosphonate
users appeared to be in better general health than the average
hip fracture patient was. A similar line of reasoning was used
by Bondo et al., because they found a lower mortality rate in
patients who had received only one prescription for a bisphos-
phonate (≤ 84 days of treatment) [24]. Furthermore, this ex-
planation is reasonable because life expectancy is
incorporated into fracture risk assessment [40], because the
anti-fracture effects of bisphosphonates may be delayed [41],
and because physicians may be concerned about side effects
in patients who are in poor health. Second, confounding could
have arisen if healthier patients are more likely to collect their
prescriptions. This explanation was not possible to assess in
our study because we did not have data about uncollected
prescriptions. Previous observational studies did not explore
this second explanation either [11, 12, 21, 22, 13–20].
Although an association soon after treatment initiation is
consistent with confounding, an early treatment effect cannot
be ruled out. From a physiological perspective, it is unclear
how soon bisphosphonates could begin to take effect on mor-
tality. Proposed physiological mechanisms include anti-angio-
genesis, slowing of atherosclerosis, improving general health
status, strengthening the immune system, and preventing frac-
tures [10, 33]. However, even the most well documented of
these effects of bisphosphonates, that of fracture reduction,
has an unclear time to onset [41]. Despite this uncertainty, a
randomized controlled trial by Lyles et al. suggested that the
Fig. 2 Kaplan-Meier estimated risk and relative risk (bisphosphonate
users versus controls) of death in the matched cohort during the first
3 years after initiation of bisphosphonate (BP) treatment. In the bottom
panel, the solid line indicates relative risk and the dashed lines indicate
95% confidence intervals
Fig. 3 Kaplan-Meier estimated risk and relative risk (bisphosphonate
users versus controls) of death in the matched cohort during the first
30 days after initiation of bisphosphonate (BP) treatment. In the bottom
panel, the solid line indicates relative risk and the dashed lines indicate
95% confidence intervals
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effect on mortality is delayed, as zoledronic acid was associ-
ated with significantly lower mortality but survival curves
were similar until the second year of treatment [2]. A similar-
ity of survival curves does not preclude an early effect, as
randomized controlled trials often are underpowered to deter-
mine time to treatment effect [42]. However, it contradicts the
findings of our study and those of most previous observational
studies that reported survival curves, as these curves diverged
early [12, 13, 15, 17, 20]. Two exceptions are one study that
displayed survival curves only for death due to colon cancer
[18] and another study that had a flawed analysis, which
guaranteed survival in the control group for at least 90 days
[19].
To clarify how early the association could be observed, we
plotted the ratio of the survival curves over time, which showed
that the association could be observed within days. This result
cannot be directly compared to the results of previous studies, as
these did not examine the association continuously over time.
However, two previous studies in hip fracture patients divided
follow-up into longer periods and showed that bisphosphonate
use was associated with lower mortality within 3 months and
within 12 months [11, 12]. These two studies in hip fracture
patients, together with the abovementioned study by Bondo
et al. [24], indicate that the early separation of survival curves
seen in observational studies of hip fracture patients and non-hip
fracture patients can be observed within months of treatment [12,
13, 15, 17, 20]. Our study adds to these data by showing that a
lower mortality rate can be observed within days.
The results of our study could not be explained by a large
number of confounders, including diagnoses, medications,
known or suspected dementia, and physical functioning sta-
tus. To control for these confounders, we used methods rec-
ommended by the epidemiology or statistics literature: imitat-
ing the exclusion criteria of a randomized controlled trial [31,
32], matching using time-dependent propensity scores [34,
35], and adjusting for time-fixed and time-varying con-
founders using regression [36, 43]. We also used methods to
avoid bias, including analyzing bisphosphonate use as a time-
varying variable to avoid immortal-time bias [36] and analyz-
ing incident users of bisphosphonates to prevent bias by the
inclusion of prevalent users [43]. Several of these strengths of
our study were also mentioned as strengths of previous obser-
vational studies [12, 13, 15, 17, 19, 20]. Although these
strengths could mean that our results reflect a true treatment
effect, our results could also be due to residual or unmeasured
confounding. Residual and unmeasured confounding are dif-
ficult to rule out because doing so requires access to variables
that accurately quantify why some patients receive
bisphosphonates while others do not. Due to this difficulty,
some researchers argue that it is rarely possible to reliably rule
out confounding in observational studies of treatment effects
[23]. Therefore, controlling for confounding was not our ap-
proach, but to assess the presence of confounding.
Although zoledronic acid was reported to reduce mortality
in the randomized controlled trial by Lyles et al. [2], our sub-
group analysis showed that the use of zoledronic acid was
associated with higher mortality. This result could be due to
chance, as the number of zoledronic acid users was small. It
could also be due to confounding in the opposite direction
(toward a harmful effect of bisphosphonates) because pa-
tients who receive zoledronic acid rather than oral
bisphosphonates may in poorer health, as Swedish guide-
lines recommend zoledronic acid for patients who do not
tolerate oral bisphosphonate or who are likely to be non-
adherent [44].
The following limitations of this study should be noted.
First, we included only hip fracture patients because we could
obtain data with many confounders for this population and
because bisphosphonate use has been consistently associated
with lower mortality in hip fracture patients [11, 12, 14, 15,
17, 24]. In other populations, confounding may be less strong
or have a different effect due to different prescribing practices.
This possibility could explain why bisphosphonates have not
always been associated with lower mortality in other popula-
tions, such as cancer patients [21, 45]. Second, we did not
have access to all confounders included in previous studies.
However, this limitation is unlikely to explain our results be-
cause, as mentioned, our results are consistent with those of
most previous studies. Third, because of limited statistical
power, it was not possible to determine whether the risk is
of death differed between bisphosphonate users and
nonusers immediately after treatment initiation (that is,
from day 1).
In sum, our study adds to the findings of previous observa-
tional studies by showing that the association of bisphospho-
nate use with lower mortality can be observed within days, not
just within months, of treatment. Although such an early treat-
ment effect cannot be ruled out due to limited evidence, it is
consistent with confounding. This uncertainty implies that our
results should not be interpreted as evidence that
bisphosphonates have a beneficial effect on mortality, even
though we avoided certain biases and controlled for a large
number of confounders. Since most previous observational
studies also showed that the association begins early, these
results may also be confounded. Therefore, they should be
interpreted with caution. Future studies that examine the
presence of confounding could compare associations in pa-
tients who are prescribed a bisphosphonate but who either
do or do not collect their prescriptions. This approach may
clarify whether results could be confounded because
healthier patients are more likely to collect their prescrip-
tions or because physicians’ are more likely to prescribe
bisphosphonates to healthier patients. Future observational
studies that examine the effect of bisphosphonates on mor-
tality should explain why confounding was reliably
eliminated.
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